Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 3, 2012, Pages 287-292

  Fiel, M Isabel ^a   Schiano, Thomas D ^b  

^a Lillian and Henry M Stratton Hans Popper Department of Pathology   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

de novo autoimmune hepatitis; hepatitis C; immune mediated hepatitis; immunologic graft dysfunction; liver transplantation; plasma cell hepatitis

Indexed keywords

ACTIN ANTIBODY; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; ENZYME ANTIBODY; EVEROLIMUS; GLUTATHIONE TRANSFERASE T1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MICROSOME ANTIBODY; SMOOTH MUSCLE ACTIN ANTIBODY; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIVIRAL THERAPY; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DRUG WITHDRAWAL; HEPATITIS C; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NOMENCLATURE; PLASMA CELL HEPATITIS; REVIEW;

GRAFT REJECTION; HEPATITIS C; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; LIVER TRANSPLANTATION; PLASMA CELLS;

EID: 84861199718     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283536622     Document Type: Review

References (43)

1. Guido M, Burra P. De novo autoimmune hepatitis after liver transplantation. Semin Liver Dis 2011; 31:71-81.
2. Liberal R, Longhi MS, Grant CR, et al. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol 2011.
3. Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transpl Int 2010; 23:971-983.
4. Fiel MI, Agarwal K, Stanca C, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14:861-871. (Pubitemid 351895516)
5. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012.
6. Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl 2008; 14:750-755. (Pubitemid 351895504)
7. Aguilera I, Sousa JM, Praena JM, et al. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. Clin Transplant 2011; 25:207-212.
8. Adeyi O, Fischer SE, Guindi M. Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation. J Clin Pathol 2010; 63:47-74.
9. Hubscher S. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl 2009; 15 (Suppl 2):S19-S24.
10. Hubscher SG. What is the long-term outcome of the liver allograft? J Hepatol 2011; 55:702-717.
11. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006; 43:1109-1117. (Pubitemid 43724635)
12. O'Grady J. The immunoreactive patient: rejection and autoimmune disease. Liver Transpl 2011; 17 (Suppl 3):S29-S33.
13. Rubin A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35:805-812.
14. Takeishi K, Shirabe K, Toshima T, et al. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case. Surg Today 2011; 41:1016-1019.
15. Ward SC, Schiano TD, Thung SN, Fiel MI. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009; 15:1826-1833.
16. Gibelli NE, Tannuri U, Mello ES, et al. Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation. Pediatr Transplant 2006; 10:371-376.
17. Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis 2011; 15:859-878.
18. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007; 7:955-963. (Pubitemid 46481195)
19. Aguilera I, Sousa JM, Gavilan F, et al. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005; 37:3968-3969. (Pubitemid 43015226)
20. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2008; 24:298-305. (Pubitemid 351535888)
21. Syn WK, Nightingale P, Gunson B, et al. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007; 13:984-989. (Pubitemid 47163190)
22. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Idiopathic posttransplanta-tion hepatitis following living donor liver transplantation, and significance of autoantibody titre for outcome. Transpl Int 2009; 22:303-312.
23. Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007; 56:237-242.
24. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001; 34:464-470. (Pubitemid 32791325)
25. Merli M, Gentili F, Giusto M, et al. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 2009; 41:345-349.
26. Pongpaibul A, Venick RS, McDiarmid SV, Lassman CR. Histopathology of de novo autoimmune hepatitis. Liver Transpl 2012.
27. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55:207-217.
28. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998; 351:409-413. (Pubitemid 28064165)
29. Anagnostis P, Efstathiadou ZA, Akriviadis E, et al. De novo autoimmune hepatitis associated with PTH(1-34) and PTH(1-84) administration for severe osteoporosis in a liver transplant patient. Osteoporos Int 2011.
30. Cho JM, Kim KM, Oh SH, et al. De novo autoimmune hepatitis in Korean children after liver transplantation: a single institution's experience. Transplant Proc 2011; 43:2394-2396.
31. Di Cocco P, Barletta A, Clemente K, et al. De novo autoimmune hepatitis following liver transplantation: a case report. Transplant Proc 2008; 40:2073-2074.
32. Oya H, Sato Y, Yamamoto S, et al. De novo autoimmune hepatitis after living donor liver transplantation in a 25-day-old newborn baby: a case report. Transplant Proc 2009; 41:433-434.
33. Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant Proc 2006; 38:1467-1470.
34. Yoshizawa K, Shirakawa H, Ichijo T, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transplant 2008; 22:385-390. (Pubitemid 351689672)
35. Zhang Y, Wang B, Wang T. De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis: a case report. Transplant Proc 2010; 42:3854-3857.
36. Kontorinis N, Agarwal K, Elhajj N, et al. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006; 12:827-830.
37. Anon. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25:658-663.
38. Aguilera I, Sousa JM, Gavilan F, et al. Complement component 4d immunos-taining in liver allografts of patients with de novo immune hepatitis. Liver Transpl 2011; 17:779-788.
39. Mieli-Vergani G, Vergani D. Autoimmune liver diseases in children: what is different from adulthood? Best Pract Res Clin Gastroenterol 2011; 25:783-795.
40. Casanovas T, Argudo A, Pena-Cala MC. Effectiveness and safety of ever-olimus in the treatment of autoimmune hepatitis related to antihepatitis C virus therapy after liver transplant: three case reports. Transplant Proc 2011; 43:2233-2236.
41. Khettry U, Huang WY, Simpson MA, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007; 38:443-452. (Pubitemid 46227528)
42. Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, et al. Risk factors for developing de novo autoimmune hepatitis associated with antiglutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009; 15:530-539.
43. Casanovas T, Argudo A, Pena-Cala MC. Everolimus in clinical practice in long-term liver transplantation: an observational study. Transplant Proc 2011; 43:2216-2219.